Market Research Report
Animal Pharm Vaccines/Forms for Bovine Mastitis 2017
|Published by||Animal Pharm||Product code||573552|
|Published||Content info||93 Pages
Delivery time: 1-2 business days
|Animal Pharm Vaccines/Forms for Bovine Mastitis 2017|
|Published: October 18, 2017||Content info: 93 Pages||
This latest report Animal Pharm describes new technical developments in the field of bovine mastitis and ruminant reproductive disease and efforts to develop new vaccines and other prophylactic approaches.
Bovine mastitis is an inflammatory condition of the mammary glands (udder) of cows. It has a significant impact on productivity, animal welfare and milk quality.
Bovine mastitis and reproductive diseases remain as largely unmet market needs from the perspective of preventive medicine. Despite a clear environmental component, mastitis control has depended heavily on the routine use of antimicrobials both for treatment of clinical cases but also for prevention as dry cow therapy.
The pursuit of prophylactics has been a holy grail for the animal health industry and veterinary academia for many years but although there a few vaccine products on the market now, this has not been very fruitful in terms of broadly effective vaccines or other products.
Attention is beginning to turn away from conventional vaccine approaches and more towards exploitation of innate immunological mechanisms.
Historically the successful control of mastitis has relied on treatment with antibiotics (antimicrobials), however in recent years it has been recognised that antibiotic usage has contributed to an increase in the prevalence of antibiotic-resistant bacterial strains.
In fact, the phenomenon of antimicrobial resistance (AMR) has become a major global health and technical challenge in both human and veterinary medicine. There is therefore a huge incentive to develop novel alternative safe products for the control of this and many other diseases.
The mastitis therapeutic market is currently estimated at about US$1 bilion per annum and thus the vaccine market potential is very attractive if the technical challenges could be overcome.
However, it is clear that there is still insufficient understanding of the immune mechanisms of the lactating mammary gland. Attention is beginning to turn towards exploitation of the innate immune system in controlling mastitis and indeed other related infectious diseases.
Vaccines for brucellosis have been available for many years. However, all have issues of safety and or efficacy and there is therefore still an unmet need for improved vaccines.